CY1115104T1 - Φαρμακα και μεθοδοι για την θεραπευτικη αγωγη της κεφαλαλγιας - Google Patents

Φαρμακα και μεθοδοι για την θεραπευτικη αγωγη της κεφαλαλγιας

Info

Publication number
CY1115104T1
CY1115104T1 CY20141100366T CY141100366T CY1115104T1 CY 1115104 T1 CY1115104 T1 CY 1115104T1 CY 20141100366 T CY20141100366 T CY 20141100366T CY 141100366 T CY141100366 T CY 141100366T CY 1115104 T1 CY1115104 T1 CY 1115104T1
Authority
CY
Cyprus
Prior art keywords
botulinum toxin
patient
headache
headphone
medicines
Prior art date
Application number
CY20141100366T
Other languages
English (en)
Inventor
Catherine C Turkel
Mitchell F Brin
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/789,180 external-priority patent/US9078892B2/en
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of CY1115104T1 publication Critical patent/CY1115104T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24069Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Μία διαταραχή κατάχρησης βραχυχρόνιων φαρμάκων πόνου (όπως μία διαταραχή κεφαλαλγίας κατάχρησης φαρμάκων) είναι δυνατόν να υποβληθεί σε θεραπευτική αγωγή δια χορήγησης αλλαντικής τοξίνης εις έναν ασθενή. Μία κεφαλαλγία είναι δυνατόν να υποβληθεί σε θεραπευτική αγωγή πλέον αποτελεσματικά δια συγχορήγησης αλλαντικής τοξίνης και μίας δραστικής ουσίας τριπτάνης εις έναν ασθενή και/ή η αποτελεσματικότητα του φαρμάκου τριπτάνης είναι δυνατόν να αυξηθεί. Η αλλαντική τοξίνη μπορεί να είναι αλλαντική τοξίνη τύπου Α και η αλλαντική τοξίνη είναι δυνατόν να χορηγείται εις το σημείο ή πλησίον αυτού, όπου ο ασθενής αισθάνεται ή έχει την προδιάθεση να αισθάνεται πόνο ή κεφαλαλγία.
CY20141100366T 2004-02-26 2014-05-23 Φαρμακα και μεθοδοι για την θεραπευτικη αγωγη της κεφαλαλγιας CY1115104T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/789,180 US9078892B2 (en) 2004-02-26 2004-02-26 Methods for treating pain and for treating a medication overuse disorder
US11/039,506 US20050191321A1 (en) 2004-02-26 2005-01-18 Methods for treating headache
EP05723092.2A EP1725253B1 (en) 2004-02-26 2005-02-15 Medicaments and methods for treating headache

Publications (1)

Publication Number Publication Date
CY1115104T1 true CY1115104T1 (el) 2016-12-14

Family

ID=34914767

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100366T CY1115104T1 (el) 2004-02-26 2014-05-23 Φαρμακα και μεθοδοι για την θεραπευτικη αγωγη της κεφαλαλγιας

Country Status (17)

Country Link
US (10) US20050191321A1 (el)
EP (3) EP2752197B1 (el)
JP (1) JP4913721B2 (el)
KR (1) KR20060126793A (el)
CN (1) CN103251937B (el)
AU (2) AU2005216887A1 (el)
BR (1) BRPI0508231A (el)
CA (2) CA2557588C (el)
CY (1) CY1115104T1 (el)
DK (1) DK1725253T3 (el)
ES (1) ES2460731T3 (el)
HK (2) HK1098072A1 (el)
MX (1) MX337511B (el)
PL (1) PL1725253T3 (el)
PT (1) PT1725253E (el)
SI (1) SI1725253T1 (el)
WO (1) WO2005082339A2 (el)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7922983B2 (en) * 2005-07-28 2011-04-12 Kimberly-Clark Worldwide, Inc. Sterilization wrap with additional strength sheet
US7223234B2 (en) * 2004-07-10 2007-05-29 Monitrix, Inc. Apparatus for determining association variables
WO2006078588A2 (en) * 2005-01-18 2006-07-27 Allergan, Inc. Improved methods for treating headache
US7749515B2 (en) 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
US7655244B2 (en) 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
AU2012241076B2 (en) * 2005-02-01 2015-05-14 Allergan, Inc. Targeted delivery of Botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
FR2889936B1 (fr) 2005-09-01 2007-12-21 Sod Conseils Rech Applic Methode pour quantifier une neurotoxine cholinergique dans un echantillon
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
FR2902341B1 (fr) * 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
US9061025B2 (en) * 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
US20080103546A1 (en) * 2006-10-27 2008-05-01 Cyberonics, Inc. Patient management system for treating epilepsy using an implantable medical device
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US8617571B2 (en) 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
US8940308B2 (en) 2010-03-30 2015-01-27 Allergan, Inc. Methods for treating depression
US10111938B2 (en) 2011-03-30 2018-10-30 Allergan, Inc. Injection paradigm for administration of botulinum toxins
BR112014000634A2 (pt) 2011-07-14 2017-02-14 Allergan Inc métodos para tratamento de incontinência associada com atividade sexual
ES2759478T3 (es) 2012-03-12 2020-05-11 William J Binder Tratamiento de las cefaleas por migraña con neurotoxina presináptica
US8491917B1 (en) 2012-03-12 2013-07-23 William J. Bender Treatment of migraine headache with diffusion of toxin in non-muscle related areas of the head
ES2424294B1 (es) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
AU2013246882B2 (en) 2012-04-13 2017-10-19 Lubrizol Advanced Materials, Inc. Compounds which inhibit neuronal exocytosis (II)
WO2014078724A1 (en) * 2012-11-16 2014-05-22 Finzi Eric Treatment of post-traumatic stress disorder using botulinum toxin a
KR20150135425A (ko) 2013-03-22 2015-12-02 리포텍 에스.에이. 피부, 점막 및/또는 손톱의 치료 및/또는 관리를 위한 세포외 다당류
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
US9254314B2 (en) 2013-11-12 2016-02-09 Eric Finzi Treatment of social anxiety disorder, obsessive compulsive disorder and panic disorder using botulinum toxin
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
JP7217700B2 (ja) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド 安定化非タンパク質クロストリジウム毒素組成物
US10456419B2 (en) 2017-02-27 2019-10-29 Payman Sadeghi Method for treating migraine headaches
US10932711B2 (en) 2017-02-27 2021-03-02 Payman Sadeghi Method and system for neurohydrodissection
US20200023044A1 (en) * 2017-03-22 2020-01-23 Bonti, Inc. Botulinum neurotoxins for treating traumatic injuries
AU2018290765A1 (en) * 2017-06-26 2020-01-23 Bonti, Inc. Clostridial neurotoxin formulations and use
AU2021240083A1 (en) * 2020-03-18 2022-10-20 Revance Therapeutics, Inc. Injectable botulinum toxin methods for treating headaches

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
AU688452B2 (en) * 1993-12-28 1998-03-12 Allergan, Inc. Botulinum toxins for treating various disorders and associated pain
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
ATE292977T1 (de) 1994-05-09 2005-04-15 William J Binder Präsynaptische neurotoxine gegen migränekopfschmerzen
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5670181A (en) * 1995-10-20 1997-09-23 Stokes; Christine P. Apparatus and method for slip casting for ceramic objects
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
MXPA01004254A (es) * 1998-10-27 2002-04-24 Mayo Foundation Metodos para intensificar la curacion de heridas.
US6358917B1 (en) * 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
PT1253932E (pt) * 2000-02-08 2005-07-29 Allergan Inc Composicoes farmaceuticas de toxina botulinica
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) * 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US6787517B1 (en) * 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
AU2002355730B2 (en) 2001-07-27 2007-09-13 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Botulinum toxin in the treatment or prevention of acne
US6623742B2 (en) * 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
DE10150415A1 (de) 2001-10-11 2003-05-15 Andres O Ceballos-Baumann Arzneimittel zur Prophylaxe und Therapie von Depressionen
AU2003212473A1 (en) * 2002-03-01 2003-09-16 Solstice Neurosciences, Inc. Methods of treating nerve entrapment syndromes
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
MXPA05009425A (es) * 2003-03-06 2006-02-10 Botulinum Toxin Res Ass Inc Tratamiento del dolor facial cronico y cefalea relacionados con la sinusitis con toxina botulinica.
US7393537B2 (en) * 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US8734810B2 (en) * 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8609112B2 (en) * 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8609113B2 (en) * 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US7270287B2 (en) * 2004-01-06 2007-09-18 Allergan, Inc. Botulinum toxin treatment for kinesia
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US8512984B2 (en) * 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8603779B2 (en) * 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US7749515B2 (en) * 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
US7655244B2 (en) * 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
TWI282083B (en) * 2005-05-27 2007-06-01 Innolux Display Corp Backlight on/off control circuit
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US20090317377A1 (en) * 2005-08-26 2009-12-24 Yeomans David C Therapy procedure for drug delivery for trigeminal pain
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
US20080021437A1 (en) * 2006-04-27 2008-01-24 Boyd James P Enhancement of the efficacy of a clenching reduction device by augmenting with botulinum toxin type A
GB0610867D0 (en) * 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
US9061025B2 (en) * 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US8617571B2 (en) * 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
EP2521453B1 (en) * 2010-01-08 2016-05-11 Beth Israel Deaconess Medical Center Combinations of vitamin d and a statin for the treatment of migraine headaches
US8940308B2 (en) * 2010-03-30 2015-01-27 Allergan, Inc. Methods for treating depression
US10111938B2 (en) * 2011-03-30 2018-10-30 Allergan, Inc. Injection paradigm for administration of botulinum toxins
BR112014000634A2 (pt) * 2011-07-14 2017-02-14 Allergan Inc métodos para tratamento de incontinência associada com atividade sexual
US8491917B1 (en) * 2012-03-12 2013-07-23 William J. Bender Treatment of migraine headache with diffusion of toxin in non-muscle related areas of the head
ES2689380T3 (es) * 2012-04-03 2018-11-13 Basf Se Composición cosmética capilar que comprende lecitina vegetal
US9005628B2 (en) * 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
EP2954318B1 (en) * 2013-02-06 2023-03-15 Agilent Technologies, Inc. Coupling devices for fluidic conduits and related methods
US20140294923A1 (en) * 2013-02-20 2014-10-02 Questcor Pharmaceuticals, Inc. Acth for treatment of migraine headache
WO2014150899A1 (en) * 2013-03-15 2014-09-25 Chapin Matthew J Topical ophthalmic formulations for treating migraine
EP3137053B1 (en) * 2014-04-30 2020-06-17 Allergan, Inc. Formulations of biologics for intravesical instillation
WO2016040039A1 (en) * 2014-09-12 2016-03-17 Allergan, Inc. Methods for treating osteoarthritis pain

Also Published As

Publication number Publication date
EP2752197A1 (en) 2014-07-09
US20220088157A1 (en) 2022-03-24
HK1098072A1 (en) 2007-07-13
CA2557588C (en) 2017-11-28
AU2011201107B2 (en) 2012-12-20
PT1725253E (pt) 2014-05-06
JP4913721B2 (ja) 2012-04-11
KR20060126793A (ko) 2006-12-08
EP1725253A2 (en) 2006-11-29
US10092631B2 (en) 2018-10-09
US20200230217A1 (en) 2020-07-23
EP2433643A1 (en) 2012-03-28
EP1725253B1 (en) 2014-04-09
BRPI0508231A (pt) 2007-07-17
US20100189655A1 (en) 2010-07-29
US10603366B2 (en) 2020-03-31
US7704511B2 (en) 2010-04-27
US9078893B2 (en) 2015-07-14
EP2433643B1 (en) 2015-12-02
US20170128552A1 (en) 2017-05-11
US20150313974A1 (en) 2015-11-05
EP2752197B1 (en) 2019-11-20
AU2005216887A1 (en) 2005-09-09
CN103251937A (zh) 2013-08-21
WO2005082339A2 (en) 2005-09-09
CA2982313A1 (en) 2005-09-09
HK1199403A1 (en) 2015-07-03
US20060104995A1 (en) 2006-05-18
CA2557588A1 (en) 2005-09-09
PL1725253T3 (pl) 2014-08-29
MX337511B (es) 2016-03-09
US20090263426A1 (en) 2009-10-22
US20190038726A1 (en) 2019-02-07
JP2007525505A (ja) 2007-09-06
US8889151B2 (en) 2014-11-18
ES2460731T3 (es) 2014-05-14
WO2005082339A3 (en) 2005-12-01
SI1725253T1 (sl) 2014-05-30
US9555085B2 (en) 2017-01-31
US20060121057A1 (en) 2006-06-08
DK1725253T3 (da) 2014-07-07
AU2011201107A1 (en) 2011-04-07
CN103251937B (zh) 2015-10-07
US20050191321A1 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
CY1115104T1 (el) Φαρμακα και μεθοδοι για την θεραπευτικη αγωγη της κεφαλαλγιας
CY1116464T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
CY1108436T1 (el) Χορηγηση καψαϊκινοειδων
DK1853250T3 (da) Kombinationer og måder til indgivelse af terapeutiske midler og kombinationsterapi
ES2177084T3 (es) Uso de derivados de benzohidrilo sulfinilo para tratar la somnolencia de origen medicamentoso.
CY1108384T1 (el) Διαδερμικη δοσολογια βουπρενορφινης για αναλγησια
ATE463249T1 (de) Pharmazeutische formulierungen von kalium-atp- kanalöffnern und deren verwendungen
CY1117656T1 (el) Επιλογες θεραπειας για τη νοσο του fabry
TR200002786T2 (tr) Meloksikam için yeni galenik bir formülasyon.
IL171607A (en) Use of botulinum toxin for the treatment of sinusitis-induced headaches
CY1115544T1 (el) Σκευασμα καψουλων πιρφενιδονης και αποδεκτων φαρμακευτικως εκδοχων
NO332893B1 (no) Anvendelse av antistoff for fremstilling av medikament til anvendelse ved CVP-kjemoterapi
EA202091999A2 (ru) Применение ингибиторов dpp iv
DE60023476D1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
ATE529113T1 (de) Salze von kalium-atp-kanal-öffnern und ihre verwendungen
GB2467691A (en) Methods for stratifying and annotating cancer drug treatment options
NO20055173L (no) Farmasoytisk kombinasjonsblanding omfattende modafinil og et annet legemiddel
NO20032027L (no) Effektive antitumorbehandlinger
NO20072931L (no) Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva
NO20064287L (no) Dalbavancin-materialer for behandling av bakterielle infeksjoner
DE602004016376D1 (de) Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
DE60330914D1 (de) Arzneimittel mit shikonin als wirkstoff
ATE484280T1 (de) Verwendung der kombination aus temozolomid und tnf-alpha zur behandlung von glioblastoma
Amorim et al. Enthusiastic claims for open-label placebo pills ignore the evidence
Arnstein The future of topical analgesics